9/25/2013

Biocept said in a regulatory filing that it looks to obtain as much as $24.25 million in an initial public offering. The California-based company specializes in cancer assays based on circulating tumor cells as well as circulating tumor DNA diagnostics, which employ blood specimens.

Related Summaries